Background: Low-grade systemic inflammation is commonly observed in conditions associated with reduced FEV 1 . Active cigarette smoking, which is a leading risk factor for decreased FEV 1 , can also independently induce systemic inflammation. Study objectives: To determine the independent contributions of active cigarette smoking and reduced FEV 1 (as well as their potential interactions) on systemic inflammation. Design: Cross-sectional survey. Setting: The US general population. Participants: A total of 7,685 adult participants, > 40 years of age, in the Third National Health and Nutrition Examination Survey, who had acceptable data on spirometry and laboratory measurements such as serum C-reactive protein (CRP). Measurements: The participants were stratified into four equal groups (quartiles) based on the percent predicted FEV 1 values. Each group was further categorized as active smokers or nonsmokers according to serum cotinine level (ie, > 10 or < 10 ng/mL). Serum levels of CRP, plasma fibrinogen, blood leukocytes, and platelets were compared across the predicted FEV 1 quartile groups and across smoking status using multiple logistic regression models. 
I
ndividuals who have reduced FEV 1 are at increased risk of morbidity and mortality from various disorders, including ischemic heart disease, stroke, arrhythmias, respiratory failure, and cachexia. [1] [2] [3] [4] Although the exact mechanism for these relationships is still unknown, many individuals with COPD and other conditions associated with reduced FEV 1 consistently demonstrate both airway inflammation 5 and systemic inflammation 6 -13 in a severitydependent fashion. Low-grade systemic inflammation is a known risk factor for atherosclerosis, 14 muscle loss, and cachexia. 12, 13 In the community, the single most important risk factor for reduced FEV 1 is cigarette smoking. 15 Since cigarette smoking by itself also can lead to systemic inflammation, 16, 17 the observed relationship between reduced FEV 1 and systemic inflammation may be confounded by cigarette smoke exposure. Furthermore, there is little information on whether reduced FEV 1 and cigarette smoking have additive, synergistic, or no combined effects on systemic inflammation. We used data from the Third National Health and Nutrition Examination Survey (NHANES 3) to determine, first, whether reduced FEV 1 , independent of active cigarette smoking, is associated with systemic inflammation in the adult population that is Ն 40 years of age, and, second, whether cigarette smoking has an additive (or even a synergistic) effect on systemic inflammation among those with reduced FEV 1 .
Materials and Methods

Study Sample
NHANES 3 was conducted from 1988 to 1994 in the United
States by the National Center for Health Statistics of the Centers for Disease Control and Prevention. This was a cross-sectional, multistage, probability representative sample of the civilian noninstitutionalized US population. 18 Once chosen, study participants were asked to complete a questionnaire and a comprehensive physical examination, which included spirometric measurements either in the household or at a specially equipped mobile examination center. The data were then collated and entered into a database. The full sampling methods and the survey protocols have been described elsewhere. 18 From the larger data set of approximately 20,000 Americans, we restricted the present analysis to the participants of NHANES 3 who were Ն 40 years of age to minimize the influences of age on markers of systemic inflammation. Of the 11,448 participants aged Ն 40 years, we excluded those who did not have reported values for smoking status, body mass index (BMI), FEV 1 , or serum cotinine level. This process left 7,685 participants for the present study. Of these, 4,291 participants were either active or ex-smokers (as indicated by the participants' own history).
Measurements
The laboratory procedures used in the NHANES 3 have been described previously. 19 Briefly, pulmonary function testing was performed in study participants according to the standards of the American Thoracic Society. 20 Each study participant performed five to eight forced expiratory maneuvers. To adjust for height, age, and gender, we used published prediction equations for FEV 1 and FVC, which were derived from the NHANES 3 population. 21 Serum cotinine level was measured by using highperformance liquid chromatography atmospheric-pressure chemical ionization tandem mass spectrometry. 22 We used serum cotinine level to differentiate active smokers from nonsmokers because cotinine is widely considered to be the best marker for monitoring tobacco exposure in either actively or passively exposed individuals. 22 In contrast to nicotine, which has a serum half-life of only 1 to 2 h, cotinine (a major metabolite of nicotine) has a half-life of 18 to 20 h. 22 Accordingly, by measuring serum cotinine levels we can monitor tobacco exposure over the preceding 2 to 3 days. This avoids the misclassification of smokers who refrain from tobacco exposure just hours prior to the examination because their serum cotinine levels will still be elevated. The serum nicotine levels may be falsely negative in such individuals. In this study, we chose a serum cotinine level of Ն 10 ng/mL to indicate active cigarette smoking. A previous study 23 using the NHANES 3 population showed that Ͻ 5% of nonsmokers have serum cotinine levels of Ͼ 10 ng/mL, and a similar proportion of individuals who actively smoke have cotinine levels of Ͻ 10 ng/mL. Thus, by using 10 ng/mL as the threshold, very few individuals in our study were misclassified. 23, 24 We chose C-reactive protein (CRP) as one of the markers of systemic inflammation for several reasons. First, CRP is an acute-phase protein that originates predominantly from hepatocytes in response to tissue damage or inflammation and, therefore, reflects the total systemic burden of inflammation of individuals. 25 The half-life of CRP is about 19 h, and is constant under all conditions of health and disease, so the major determinant of serum CRP is hepatic synthesis rate. 25 Second, CRP is stable and has little or no seasonal or diurnal variation, except during exacerbations or infections. 25 The self-correlation coefficient of CRP levels measured years apart is 0.5, a value that is similar to what would be expected for serum cholesterol levels. 25 Most importantly, in the community, serum CRP is a wellestablished independent risk factor for cardiovascular mortality and all-cause mortality. 26 -28 Because most participants had CRP levels below the lowest detectable limit for this assay (ie, 2.1 mg/L), CRP levels were categorized as undetectable (Յ 2.1 mg/L) or elevated (Ͼ 2.1 mg/L). Plasma fibrinogen levels, and blood leukocyte and platelet counts were also determined using standard assays, as previously described. 19 Blood leukocyte count, platelet count, and fibrinogen levels were deemed to be elevated if their values exceeded the 85th percentile for each marker. For leukocytes, the 85th percentile was Ն 9.1 ϫ 10 9 cells/L, for platelets it was Ն 339.0 ϫ 10 9 cells/L, and for fibrinogen it was Ն 3.9 g/L.
Statistical Analysis
The population was divided into four equal groups (quartiles) based on the percentage of predicted FEV 1 values. Statistical comparisons of baseline characteristics of the study population in quartiles of FEV 1 were performed, using a 2 test for binary variables and a t test for continuous variables. To evaluate the effects of active cigarette smoke exposure on the relationship between FEV 1 and various systemic inflammatory markers, we further classified persons in the study population according to their serum cotinine levels (active smoker, Ն 10 ng/mL; nonsmokers, Ͻ10 ng/mL). The latter group was composed of life-time nonsmokers and ex-smokers. Using those with serum cotinine levels of Ͻ 10 ng/mL and the best FEV 1 (quartile 4) as the referent, we performed multiple logistic regression analyses. To this model we added age, sex, race, and BMI as covariates. The latter was divided into quintiles and was expressed in kilograms per square meter. We also performed similar analyses using blood levels of leukocytes, platelets, and fibrinogen as the dependent variables. To test the robustness of the findings, in another model, we included all of these variables plus the presence of self-reported heart disease, cancer, diabetes, arthritis, hypertension, high cholesterol, and active use of systemic corticosteroids and aspirin. All tests were two-tailed in nature and were performed using statistical software (SAS, version 8.2; SAS Institute; Cary, NC; and SUDAAN, release 8.0; Research Triangle Institute; Research Triangle Park, NC). Analyses were performed with and without NHANES 3 weights. As the results were similar, we presented data from the unweighted analysis for parsimony.
Results
The baseline characteristics of the study population are summarized in Table 1 . Quartile 1 (lowest FEV 1 ) contained more whites, more active smokers, and more men than quartile 4 (highest FEV 1 ). Individuals in quartile 1 tended to be older than those in quartile 4. There were no significant differences in the BMI across the quartiles. Crudely, those in quartile 1 had higher leukocyte, fibrinogen, and CRP levels than those in quartile 4 ( Table 1) . Adjustments of various factors such as age, sex, BMI, race, and smoking status made little difference to the overall results (Table 2 ). There was a clear gradient in the levels of leukocytes, fibrinogen, and CRP (Table 2 ). More importantly, there appeared to be an additive effect between serum cotinine values and FEV 1 quartile groups. For instance, using those in quartile 4 (best FEV 1 ) with serum cotinine levels of Ͻ 10 ng/mL (nonsmokers) as the referent group, active smoking (ie, serum cotinine level, Ն 10 ng/mL) was associated with an odds ratio (OR) of 1.63 for having elevated CRP levels. The OR for those in quartile 1 (worst FEV 1 ) having serum cotinine levels of Ͻ 10 ng/mL was 2.27. However, in quartile 1, for those who had a serum cotinine level of Ն 10 ng/mL, the OR was 3.31, indicating an additive effect of reduced FEV 1 and active smoking on CRP levels (Fig 1) . Similar findings were observed for blood leukocyte and plasma fibrinogen levels. Consistently, those in quartile 1 and with serum cotinine levels of Ն 10 ng/mL had the highest odds of having elevated levels of systemic markers of inflammation. Adjustments for age, sex, BMI, comorbidities, and select medications did not materially change the overall findings (Table 3) . The findings were similar between those with an FEV 1 /FVC ratio of Ͻ 0.7, indicating obstructive airways disease (Table 4) , and those without obstructive disease (FEV 1 /FVC ratio Ն 0.7) [ Table 5 ]. In both groups, the group that had elevated serum cotinine levels and the lowest FEV 1 had the highest levels of inflammatory markers, while the group that had a normal serum cotinine level and the highest FEV 1 had the lowest levels of inflammatory markers. When we restricted the above analysis by using 4,291 active smokers and ex-smokers (as indicated on the participant's history), the results were similar to those of the main analysis (Table 6 ).
Discussion
The most important and novel finding of this study was that active cigarette smoking and poor FEV 1 had an additive effect on systemic markers of inflammation. Individually, active smoking (as defined by a serum cotinine level of Ն 10 ng/mL) and reduced FEV 1 (as defined by an FEV 1 of Յ 83.2% predicted) were associated with 1.6 and 2.3 increased odds of elevated CRP, respectively. For individuals with both of these risk factors, the odds increased by 3.3-fold, indicating an additive response. Similar findings also were observed for serum leukocyte and plasma fibrinogen levels. These findings are consistent with previous observations, 16, 17 demonstrating that cigarette smoking contributes significantly to persistent low-grade systemic inflammation in susceptible individuals. As well, our findings suggest that, independent of active smoking, poor lung function is an important risk factor for low-grade systemic inflammation.
The mechanism for the latter observation is not entirely clear. However, there is compelling evidence to suggest that disorders such as COPD, one of the leading causes of reduced FEV 1 in the general population, have a strong inflammatory component in the airways, 5,29 which persists even after smoking cessation. 30, 31 It is highly plausible that this inflammatory component may "spill over" into the systemic circulation, leading to a state of low-grade systemic inflammation. [32] [33] [34] [35] The intensity of the systemic inflammation is further amplified by active smoking.
We also found that individuals with reduced FEV 1 on the basis of a restrictive disorder had evidence of systemic inflammation, suggesting that lung inflammation in general, regardless of the exact cause, may result in systemic inflammation. The present study has several strengths. First, it was conducted using a large representative sample of the US population, providing sufficient statistical power to evaluate the potential interaction between active smoking and reduced FEV 1 on various markers of systemic inflammation. Second, due to the very nature of NHANES 3, we were able to use a validated biochemical marker of tobacco exposure, serum cotinine, thereby minimizing smoke exposure misclassification, which has been seen in studies that exclusively rely on patient history. Third, we were able to control for important confounders such as age, sex, race, and BMI, making our findings reliable and valid.
There were several limitations to the current study. First, because NHANES 3 was a cross-sectional study, the temporal nature of the relationships among active smoking, reduced lung function, and elevated levels of inflammatory markers is uncertain. It is plausible, though unlikely, that systemic inflammation may lead to reduced lung function and not the other way around. Future prospective studies are needed to better understand the temporal associations of these relationships. Second, although the study adjusted for many factors, due to the observational nature of the study, residual confounding by these and other variables might still play a role.
Third, the NHANES 3 database did not adequately capture information on active infections or exacerbations. Since CRP and other inflammatory markers may increase during these episodes, confounding by these factors may have been present. However, it is unlikely that this would have materially affected the overall results since a vast majority of individuals in this survey were stable at the time of the examination. Finally, the NHANES 3 database did not have extensive information on comorbidities or medications. However, it was reassuring that the inclusion of self-reported conditions such as heart disease, cancer, diabetes, arthritis, hypertension, high cholesterol, and active use of systemic corticosteroids and aspirin into the regression model did not materially alter the overall findings of the study. This suggests that the findings were not confounded by these factors.
In conclusion, our study findings suggest an additive effect of active smoking and reduced FEV 1 on various markers of systemic inflammation. Since persistent low-grade systemic inflammation is associated with various complications, including cachexia and cardiovascular morbidity and mortality, our findings may explain why certain disorders, such as COPD, are associated with these systemic complications and why active smoking accelerates the risk of such complications in these patients. These data further emphasize the value of smoking cessation in patients with reduced lung function. However, our findings also suggest that smoking cessation alone helps to maintain, but may be insufficient to fully normal- ize, blood levels of CRP and other inflammatory biomarkers if compromised lung function has already developed.
